Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Long-term efficacy and safety of transanal irrigation in multiple sclerosis.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
Spectrophotometric Determination of Serum Copper with Biscyclohexanoneoxalyldihydrazone
Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking.
Neuroprotection in a novel mouse model of multiple sclerosis.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?
The role of natural killer cells in multiple sclerosis and their therapeutic implications.
The force awakens: insights into the origin and formation of microglia.
17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
Assessment and Imaging of the Cerebrovascular Glycocalyx.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity.
US and EU regulatory authorities accept oral BG-12 marketing applications for review
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
GlaxoSmithKline Product Development Pipeline
Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases.

Pages